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A Taxonomy of Value in Clinical Research
Abstract
Medical research that involves human subjects presents what appears to be an intractable ethical
problem: patients are exposed to risks in order to create valuable knowledge. A central goal of research is
to produce knowledge that is "important," "fruitful," or that will have "value." Indeed, federal regulations
require that research risks be reasonable in proportion to potential benefits, and in proportion to the
importance of the knowledge to be gained (45 CFR 46.111(a)(z)). Moreover, one reason that subjects
participate inresearch is to produce knowledge that will benefit others.
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edical research that
involves human subjects
presents what appears to
be an intractable ethical problem:
patients are exposed to risks in
order to create valuable knowledge. A central goal of research is
to produce knowledge that is
"imp~rtant,"~
"fr~itful,"~
or that
will have "value."3 Indeed, federal
regulations require that research
risks be reasonable in proportion
to potential benefits, and in proportion to the importance of the
knowledge to be gained (45 CFR
46.111(a)(z)).Moreover, one reason that subjects participate in
research is to produce knowledge
that will benefit others.4
Unfortunately, the concept of
value in research has received little
attention, particularly as it relates
to the ethics of research. While
value has been described convincingly as central to ethical research,s
it is less than clear how value
should be measured. Nor has there
been substantive discussion about
how assessment of value should
contribute to the ethical review of
research.
This lack of discussion is puzzling because other ethical requirements of research have received
considerable attention and have
been extensively specified. For
instance, the U. S. Common Rule
explicitly mandates consideration
of a study's risks relative to its
potential benefits, f d e r describ-
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ing risks as being minimal, a minor
increase over minimal risk, or
greater than minimal risk (45 CFR
46). Moreove~;these regulations
are clear about the need for
informed consent (45 CFR 46.116)
and for written documentation of
such consent (45 CFR 46.117), and
subjects are said to be capable of
consent, assent, or neither.
Although these categories may not
be universally endorsed, they
nonetheless have provided a useful
structure for protecting human
subjects.
There has recently been heated
debate about how to think about
"acceptable" risk in studies that
offer little (if any) prospect of benefit.6-8As a result, IRBs are increasingly pressured to assess the value
of a study-that is, the importdince
of the knowledge to be gained
from i t - a s part of their ethical
review. In its final report, the
National Bioethics Advisory
Commission urged that IRBs
assess, for each component of a
proposed study, the balance
between the risks it poses to subjects and the knowledge it is likely
to yield.9 This "risk-knowledge"
standard offers IRBs guidance in
implementing the Common Rule
requirement that research risks be
reasonable with respect to potential benefits and value.
If investigatorsand IRBs are to
consider value as rigorously as they
do risks and potential benefits,
they require additional conceptual
tools. Specifically, they need a taxonomy of value whose categories

promote an open and informed discussion like the deliberations now
undertaken about risks and potential benefits. In this paper, we suggest such a taxonomy.
We propose that IRBs should balance a study's risks, potential benefits (if any), and value by considering two kinds of value: immediate
health value and future health value.
We propose further that IRBs
should decide whether a study offers
either of these kinds of value to
future patients, to the population
from which the subjects are selected,
and/or to the subjects themselves.
We contend that the resulting categories provide a common framework for assessing value in clinical
research. In some cases, when risk
and value must be balanced, these
categories can help IRBs and investigators to do so. We conclude by
describing ways in which these categories can help IRBs and investigators to address some of the most
pressing problems raised by human
subjects research.
Assessing Value

11 studies must use techniques of

A
design and data analysis that
peer reviewers can agree are appro-

priate and adequate to produce
knowledge that is generalizable.
Indeed, generalizability is the cornerstone of the Common Rule definition of research: "a systematic
investigation, including research
development, testing and evaluation,
designed to develop or contribute to
generalizable knowledge" (45 CFR
46.102(d)).These requirements collectively describe a study's validity.l0
Validity is a threshold requirement
for all research, because it is unethical to expose human subjects to
risks in studies that cannot adequately answer the research question." At a minimum, thus, investigators and IRBs must consider a
study's validity.
Above this threshold of validity,
studies also offer value. But IRBs
may find it difficult to assess value
for several reasons. First, there are

numerous dimensions on which they
might base their assessment. For
example, IRBs might assess value
based on characteristics of the disease or problem under study, such
as its prevalence, or the loss of life
or decrease in function that it causes. Or they might assess a study's
value based on public perceptions of
the importance of the disease or
problem, or according to whether
the study's results are likely to
enhance quality of life, decrease
morbidity, or decrease mortality. All
of these offer plausible guides for
assessing value, and the choice
among them is not clear.
Second, IRBs face the challenge
of measuring a study's value. Even if
IRBs could agree on a single dimension of value, the examples above
suggest that value is a continuous
variable. It will be difficult for IRBs
to balance a study's risks against its
value without categories of value
that are analogous to categories of
risks.
Third, value may not be distributed uniformly-that is, a study
may offer value to some groups but
not to others, raising concerns of
justice and appropriate selection of
subjects. As the Belmont Report
notes, research should not focus on
"persons from groups unlikely to be
among the beneficiaries of subsequent applications of the
research."" This requirement is also
codified in the federal regulations
governing research that involves
children (45 CFR 46. 306(a))and
prisoners (45 CFR 46.406(c)).
These challenges suggest that any
taxonomy of research value should
have three properties, it should:
clearly identify and define a single
dimension of value; divide that
dimension into clear categories of
value, analogous to the categories of
research risks and benefits; and be
sensitive to fairness of distribution
among potential beneficiaries.
Defining Value

ollowing Emanuel and colleagues
we define value as a study's
potential to improve health and

F

well-being.'3 This definition enjoys
wide support and is codified in the
Nuremberg code as the necessity of
producing "fruitful results for the
good of society."'4 Similarly, the
Declaration of Helsinki proposes
that a fundamental goal of all biomedical research is "to help suffering humanity. " ' 5
Given the range of research that
involves human subjects, any definition of value must necessarily be as
broad as possible, while at the same
time retaining enough specificity to
be meaningful. Therefore we understand value to mean the potential of
a study to improve health, broadly
construed as biological, psychological, or social well-being.16 Studies
that promise to improve individuals7
biopsychosocial well-being have
"health value."
Health value can be categorized
along two dimensions: immediate
versus future health value, and the
population that receives this value.
Immediate vs. Future Health
Value

study has immediate health
value if experts believe that its
results can be immediately applied
to improve health and well-being.
Other studies may produce knowledge that advances understanding of
health or illness but will not immediately improve health. These studies have future health value.
Examples of studies that offer
immediate value span the spectrum
of clinical and nonclinical research.
Some of the most obvious are phase
I11 trials of new medications. If a
phase I11 trial finds that the investigational drug under study is effective, it has the potential to improve
the health of patients as soon as the
drug receives regulatory approval.
But other nonclinical studies offer
immediate value as well. For
instance, a study of needle-sharing
practices among intravenous drug
users might produce results that
could be translated immediately into
more effective educational interventions to promote safer behavior.
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Similarly, epidemiologic studies that
define the prevalence of child abuse
in a population could be used to
promote legislation or social service
interventions.
Examples of studies that offer
future health value are numerous as
well. One of the most widely discussed and debated is the phase I
trial, which is a preliminary test of a
~otentialtherapy's safety. Even if a
~otentialtherapy is demonstrated to
be safe in a phase I trial, its effectiveness has not yet been demonstrated. The results of a phase I trial
cannot be applied immediately to
improve health and well-being.
Other research that offers future
value includes studies of normal psychological function, ethnographic
studies of social interaction, or studies of normal physiological function.
In general, the results of these sorts
of studies may advance understanding and they may lead to future
studies that improve health and
well-being. However, they are
unlikely to produce results that
could directly improve health and
well-being. Their value lies in their
contribution to future research.
The distinction between immediate and future value is ethically
important because, in general, a
study that offers immediate value
offers far greater certainty of an
effect on health and well-being. If
value is an ethical requirement of
research, then the threshhold of
immediate (vs. future) value seems
logical. For instance, further testing
that is necessary after a phase I trial
(e.g. phase I1 and phase 111 trials)
introduces uncertainty as to whether
an intervention that is tested in a
phase I trial will ever be applied in a
clinical setting to improve health.
Similarly, the scientific threads that
connect studies of normal physiology with future studies that offer
health value are usually difficult to
discern. Of course, even with a
phase 111 trial that promises immediate health value, there is uncertainty
whether the intervention will be
effective, and whether the agent will
be approved and clinically available.
I R B : E T H I C S& H U M A N R E S E A R C H

Nevertheless, there is far greater certainty that a phase 111 study will
produce an improvement in health
or well-being than there is for virtually all phase I studies.
This distinction between immediate and future value is based on a
judgment about whether a study's
results will improve health or wellbeing. It does not include a judgment about the magnitude of those
improvements, the number of
patients who might benefit from
them, or the amount of time that it
will take to complete the study.
Thus a study that takes several years
to complete has immediate value if
its results will produce even a minor
improvement in the health of a few
patients. But if another study's
results cannot immediately improve
health, it would have only future
value, even if its results will pave the
way for future improvements for
large numbers of persons.
Two caveats are essential here.
First, it is important to note that
these determinations of value should
be made a priori, during a study's
design and IRB review. For instance,
an IRB could conclude that a phase
111 study of a new medication has
immediate value. This assessment is
still valid even if, at the study's conclusion, the newer medication is
found to be less effective than standard care. Indeed, when a study is
designed to test the equivalency of
two or more therapies that are currently in clinical use, a negative
result might offer considerable
immediate value, if one of the therapies offers substantial advantages in
terms of its side effect profile, convenience, or cost.
Second, these assessments are
probabilistic. That is, they are made
under conditions of uncertainty and
must rely on the best information
available. For a study to have immediate value, experts need to agree
that there is a reasonable possibility
of producing results that would
improve health and well-being.

Health Value for Croups of
Individuals
o see how health value can be
assessed in a way that is sensitive to concerns about justice, it is
necessary to consider how a study
may offer value to different groups
of patients. There are three groups
for whom IRBs should assess health
value: future patients, the population from which the research subjects are selected, and the subjects
themselves. (Table.)
Health Value for Future
Patients.The broadest group for
whom value can be assessed is that
of unidentified future patients, to
whom we implicitly refer when we
use the common phrase "benefits to
society." If a study is to offer value
to future patients, its results must be
generalizable. This means that the
sample of subjects in the study must
be representative. And the study
must be designed to answer a question about which there is genuine
uncertainty.
A randomized controlled trial to
determine whether an intervention is
effective in treating a condition
might offer immediate value to
future patients, as might a study to
evaluate a new diagnostic test.
Studies to define the prevalence of a
public health threat or a threat to
quality of life, such as job-related
stress, would meet this criterion as
well if their results could be translated into programs or policies to promote timely detection and intervention.
Studies that offer future value to
future patients are those that may
lead to subsequent studies whose
knowledge will improve the health
of others. A wide variety of studies
offer this category of value. For
instance, studies to define mechanisms of cell physiology do not produce results that will immediately
improve health, but may lead to
other research that would. The same
is true of studies of normal cardiovascular physiology, descriptive
studies to identify potential biomarkers of a disease, and phase I trials of new medications.
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Health Value for the Subject
Population. An IRB could also
determine whether the study is likely to produce either immediate or
future health value for a second
group: the population from which
the study participants are selected.
The answer to this question is
important because it is sensitive to
concerns about justice in research
design and recruitment. Specifically,
this question assesses the concordance between those who are likely
to be recruited into a study and
those who stand to benefit from a
study's results.
If a study is to offer immediate
health value for the target population, several conditions need to be
met. First, members of that population must have access to any
improvements in health or health
care that the study p r o d ~ c e s . ' ~ ~ ' ~
This requires that a health care
delivery system exist to provide
patients affordable access to a treatment or test. Moreover, the
providers in that health care system
must be able to learn of the research
results and must be able and willing
to apply them in clinical care. For
nonclinical research, such as a study
to assess the prevalence of elder
abuse among emergency room visits, this requires a plan to translate
results into case-finding procedures,
policy, or services.
A study that cannot meet these
requirements would provide only
future health value to the study population. One example might be a
clinical trial of an HIV therapy in
underdeveloped countries where
that therapy is not currently available. Another would be a study that
is conducted in a population whose
members would not have access to a
new medication that proves to be
effective because of cost or a restrictive formulary system.
Some studies offer neither immediate nor future health value to the
population from which subjects are
drawn. In general, these are studies
that ask a question that is not relevant to that population, although it
may be relevant to future patients

not in the population. One example
is a study that involves terminally ill
cancer patients to test a new medication, like an HIV vaccine, that is
not related to end-of-life care.
Another example is a phase I trial
that involves healthy subjects who
do not have the disease that the
study agent is targeted to treat.
These studies offer neither immediate nor potential future clinical
value for the population of subjects
who are involved.

Health Value for Research
Subjects. Finally, a study's value can
also be assessed for the subjects
themselves. Like assessments of
value to the study population, this
measure, is sensitive to concerns
about justice. If subjects take risks
and assume burdens of research in
order to produce knowledge about
a disease, test, or treatment, those
subjects have a stronger claim than
other patients on any future
improvements to health and wellbeing that may result. Benefits from
the results of a study are distinct
from other potential benefits, such
as improved health or decreased
symptoms, which may accrue to
subjects over the course of a study.
Subjects may benefit from a study's
results but not from their participation in the study, or vice versa.
Benefit from the results of a study is
also distinct from other indirect or
"collateral," benefits of participating in research.'g For instance, subjects in a study may benefit if tests
reveal an undiagnosed medical condition. However, these subjects will
not necessarily benefit from the
aggregate results of the study, which
define a study's value.
Three conditions must be met if a
study is to offer immediate health
value for its subjects. First, the disease or condition under study must
be chronic or relapsing. This makes
it possible that the knowledge generated by the study will be relevant
to the subject's care when the study
is completed. For example, the
knowledge generated by a study of
hypertension or sleep apnea is likely
to benefit the subjects themselves

because knowledge related to their
disorder will be relevant to their on
going care. O n the other hand, the
knowledge generated by a study of
resuscitation for trauma patients
would benefit the subjects only in
the unlikely event that they suffer
similar trauma again--even if such a
study offered subjects potential
direct medical benefits due to the
research intervention, it would not
offer immediate health value,
because they would be unlikely to
benefit from the knowledge to be
gained.
Second, the subjects enrolled
must live long enough to benefit
from the knowledge produced.
Subjects in a trial comparing two
anti-hypertensive agents are likely to
benefit from the study's results,
whereas cancer patients who enroll
in phase I trials of chemotherapy
agents are unlikely to benefit from
knowledge about the efficacy of
those agents. They are unlikely to
survive long enough to participate
in future studies, or to receive the
agent as part of clinical care.
However, other phase I trials may
offer future health value to participants-for example, a phase I trial
of gene therapy for genetic disorders
that may produce effective therapies
in the future. If such a study were to
enroll subjects with a mild form of
the disorder, who have a favorable
prognosis, they themselves might
benefit from future therapies that
resulted.
Third, if a study is to offer immediate or future value for subjects,
there must be mechanisms in place
to translate clinically relevant
knowledge into improved care. This
means that the results of a study
must be shared with the subjects or
their healthcare providers. This
might involve a letter or telephone
contact to the subjects, or to each
subject's physician, outlining the
study's results for clinical practice.
Clinical research centers devoted to
diseases such as cancer, asthma, or
Alzheimer's disease have an infrastructure that is ideally suited to
achieve this requirement by providIRB: ETHICS& HUMAN RESEARCH

ing rapid feedback to clinicians, and active eduTable
cation programs for
Features that Enhance a Study's Value
patients and families.
Subjects must also
Value for
Value for Research
Value for the Study
have access to therapies
Future Patients
Population
Subjects
that prove to be beneficial. if a medication has
* Study focuses on
Results are generalizable
Current or planned mechabeen approved for clininisms exist t o translate results chronic/relapsing condition
cal use, subjects must
into improvements in
Study has clinically realistic
have access to it through
inclusion criteria
Subjects have adequate life
care/policy
their pharmacies and
expectancy t o benefit
health plans, which furResearch question(s) are
An intervention that proves
ther means they must
relevant t o health and wellInvestigators have described
t o be effective will be availhave the health insurmechanisms o f follow-up and
being
able t o the population
ance or resources necescontinued contact with subsary to obtain it. A
jects
Research question(s) are
study of a medication
relevant t o the population
that has not been
approved for clinical use
of value are not necessary when all
ed. This requirement is an extension
would have immediate clinical value
of
a
study's
risks
are
outweighed
by
of the Common Rule's regulations
only if subjects have access to the
its potential benefits to subjects
governing research that involves prismedication through an open label
themselves. If no additional risks or
oners, which requires that research
phase. That is, if a medication has
burdens are imposed in order to
involving these vulnerable subjects
not yet been approved, the only way
gather generalizable data, an IRB
be designed to advance knowledge
in which research subjects stand to
need not consider the study's riskabout conditions that are relevant to
benefit from the study's results
value balance. Similarly, when a
that population (45 CFR 46.306).
immediately is if the medication is
study offers no potential benefits,
made available through an open
If a study recruits vulnerable
label continuation trial.
but also poses only minimal risks
patients, and offers immediate health
(e.g., an anonymous survey, or most
value to future patients, it should
also offer immediate health value to
Balancing Risks, Potential Benefits ethnographic research) value need
not be considered; a requirement of
the population from which the study
& Value
validity is sufficient.
subjects are selected. This require2'-'his analysis is useful only if it
There are three categories of stud- ment should be applied to most clinih e l p s IRBs to determine whether
ies, however, for which value should
cal trials. For instance, a study of
a study's risks are balanced by its
be
assessed.
First,
IRBs
should
assess
two anti-hypertensive medications
benefits and by the importance of
a
study's
value
for
the
subject
poputhat offers immediate health value
the knowledge to be gained as federlation
if
it
recruits
from
a
vulnerable
for future patients, and recruits subal regulations require (45 CFR 46.11 1
or
captive
population,
jects from a disadvantaged inner-city
i.e.,
those
(a)(z)).Specifically, an IRB must conpopulation,
should offer the same
who
are
"relatively
(or
absolutely)
sider whether a study's risks are reaincapable
of
protecting
their
own
value
to
the
study population. This
sonable in relation to its benefits,
means
that
the
study's results must
interests."'"
These
populations
might
and whether any risks without correinclude
adults
with
cognitive
impairbe
applicable
to
the population.
sponding benefits are reasonable in
ment,
residents
in
chronic
care
faciliMore
importantly,
there should be
proportion to the knowledge to be
adequate systems of health care
gained (45 CFR 46.1 1 1 (a)(2)).It is in ties, patients in intensive care units,
and underserved populations both in delivery and adequate access to care
the second analysis that IRBs might
this country and abroad. These popto ensure that the results of that
use the categories described above.
ulations are particularly susceptible
research reach that population.
This analysis requires the IRB to
to opportunistic recruiting that takes Similarly, if pharmaceutical trials
focus on the components of the
advantage of limited knowledge or a that offer immediate value in the
study that are designed solely to
paucity of alternatives to research
developed world are conducted in
answer a research question.
underdeveloped countries, they
participation.
To
offset
this
risk,
and
It is important to note, though,
to
discourage
opportunistic
recruitshould offer immediate value to
that IRBs need not use these cateing, IRBs should consider the value
patients in those countries as well.
gories for guidance in reviewing all
that a study promises to the populaThe second class of studies for
studies. For instance, considerations
tion from which subjects are selectwhich this taxonomy is useful are
IRB: ETHICS & H U M A N R E S E A R C H

those in which the study's risks are
significant, there are no potential
benefits to subjects, and the subjects
themselves are unable to give
informed consent, such as a washout study that involves patients with
active schizophrenia. This study
may pose substantial risks to the
subjects but offers little or no direct
medical benefit if subjects would be
responsive to standard the rap^.^'
The substantial ethical concern
posed because the subjects themselves do not stand to benefit directly from research participation in
such cases are magnified by challenges of informed consent.
These concerns may be ameliorated if a study's results will have
immediate health value for the subjects themselves. Direct benefits
from the knowledge to be gained
are distinct from benefits derived
during the study as we have seen,
but can nevertheless offset some of
the risks of study participation.
IRBs should thus determine whether
such high risk studies are likely to
offer immediate health value for the
subjects themselves. For instance, if
a wash-out study could determine
whether a medication is effective,
investigators should be prepared not
only to describe how the results of
the trial will be relayed to the subjects or their clinicians, they should
also be able to outline plans for
ensuring access to this new therapy.
A third class of studies for which
this taxonomy of value is useful are
studies that present greater than
minimal risks but offer no prospect
of direct benefit, such as phase I trials. For these studies, at least for
patient-subjects, altruism should
arguably be the most important reason that subjects enroll. IRBs and
investigators have an important
opportunity to take this altruism
seriously by incorporating a description of value into the informed consent process and the informed consent document itself. Ideally, the
informed consent process for these
trials should include a description of
the value that the study will offer
using the categories outlined above,

in language that is easily understandable. This disclosure can help a
potential subject to determine
whether the research risks are reasonable in proportion to his or her
desire to help others.
Moving Debate Forward
e describe a taxonomy of
value that should be useful to
investigators and particularly to
IRBs in assessing the ethics of proposed research. This taxonomy
relies on the concepts of immediate
and future health value and considers the persons who are likely to
benefit from the knowledge to be
gained. Together, these concepts
provide necessary structure to the
assessment of the importance of the
knowledge to be gained from the
research.
It should be noted, however, that
this taxonomy should be open to
discussion. Like categories of risk,
benefit, and informed consent, categories of value must be further
refined through deliberation among
investigators, IRBs and the public.
For instance, to refine categories of
value, it will be important to understand the way that subjects and
their families understand value. In
addition, discussion is needed to
determine how investigators and
IRBs can efficiently and fairly apply
a taxonomy of value.
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